Seegene, Samsung Enter Cancer MDx Pact | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Seegene and Samsung Medical Center today said they will collaborate to develop new molecular diagnostics tests directed at cancer.

The partnership combines Seegene's MDx technology with Samsung's clinical and disease pathology expertise, the two firms said. They added that Samsung will provide the first test sites for the diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.